华蟾素注射液联合TACE治疗中晚期原发性肝癌临床观察(1)
 |
| 第1页 |
参见附件。
【摘要】 目的 观察华蟾素注射液联合TACE治疗中晚期原发性肝癌的临床疗效。方法 选择确诊为中晚期原发性肝癌患者78例，随机分为华蟾素联合治疗组和TACE单纯治疗组两组。结果 联合组和对照组有效率差异无统计学意义，但华蟾素治疗组患者的生活质量明显高于单纯治疗组，而且12个月以上的生存率显著高于对照组;治疗3个周期后，联合组患者的各项实验室指标优于对照组，差异有统计学意义。结论 TACE联合华蟾素治疗肝癌可以减轻TACE对肝功能的损害程度,同时提高机体免疫功能, 延长生存期, 是中晚期肝癌一种较理想的治疗方法。
【关键词】
华蟾素；原发性肝癌；肝动脉化疗栓塞
Clinical observation of patients with primary liver cancer treated by Cinobufagin Injection combined with transcatheter arterial chemoembolization(TACE)
KE Jun, LU Kui, LI Yang. Department of Oncology, Jiangyan People’s Hospital，Jiangyan，225500，China
【Abstract】 Objective
To observe the clinical effect of Cinobufagin Injection combined with transcathete rarterial chemoembolization(TACE) on treating primary liver cancer. Methods 78 patiens with moderate and advanced primary liver cancer were randomly divided into treatment group which treated 38 patients by Cinobufagin Injection combined with TACE, and control group, which treated 40 patients by TACE only. Results The life quality of patients in treatment group was obviously higher than that in control group, and the over12month survival rate of treatment group was significantly higher than that of control group, while the difference of the effective rate between the two groups had no statistically significant. The laboratory tests after three cycles of treatment group were better than that of control group, and the difference between the two groups was statistically significant. Conclusion Cinobufagin Injection combined with TACE can decrease the damage on liver by TACE, prolong survival time, and improve body immunity.
【Key words】
Cinobufagin Injection; Primary liver cancer;Transcatheter arterial chemoembolization
原发性肝细胞癌(Hepatocellular carcinoma, HCC)是我国常见的恶性肿瘤之一, 在我国肿瘤相关死亡中仅次于肺癌, 位居第2位。据调查，80%~90%的肝癌患者同时伴有肝硬化[1]。HCC起病隐匿, 症状不明显, 一旦发现多属中晚期, 自然生存率不超过半年, 5年生存率低于5%,目前对于原发性肝癌尚无较为有效的治疗手段[2]。经动脉化疗栓塞术(Transarterial Chemoembolization, TACE)是不可手术HCC的治疗主要手段之一, 但存在副作用较大的缺点, 往往损害肝功能, 降低机体免疫力, 导致生活质量下降。2006年2月至2008年3月我们作者华蟾素注射液联合TACE治疗中晚期HCC取得了较好的临床效果, 同时显著减轻了TACE导致的副作用，现报告如下。
1 资料与方法 ......
您现在查看是摘要介绍页，详见PDF附件(2757kb)。